NAD+ precursor supplement

NMN (Nicotinamide Mononucleotide)

NMN taken by mouth raised blood NAD+ in randomized trials of healthy adults at 250 to 900 mg a day, and the app lists its half-life as 5 hours, while the app's note gives a plasma half-life of about 5 to 10 minutes.1,2

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

NMN (Nicotinamide Mononucleotide) after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.

Drawn from the half-life in the app's model, ~5 h. The model's figures

Half-life ~5 h~5 h; the app's note gives a plasma half-life of about 5 to 10 minutes Reported in the sources No half-life figure for NMN in people was identified in the trial reports read. The single-dose sampling windows read were 60 minutes in Wakabayashi and colleagues' crossover trial, whose authors say it "precluded the estimation of a full pharmacokinetic profile, including key parameters such as Tmax and total AUC", and 4 h in Christen and colleagues' study.6,4 App's figureIn the half-life and pharmacokinetics table Time to peak ~0.25 h Reported in the sources After 1,000 mg of NMN in 15 healthy adults, whole-blood NMN was not affected, "with no change in the circulatory NAD+ metabolome over 4 h"; the authors note a longer time frame might have captured a longer-term acute effect.4 After 250 mg tablets given orally or sublingually to 13 analysed men, "Blood NMN concentrations showed no change from pre-dose levels with either administration method" over 60 minutes.6 App's figureIn the half-life and pharmacokinetics table Bioavailability 60% Reported in the sources No oral bioavailability figure for NMN was identified in the reports read. Pencina and colleagues report that "Very little unmodified NMN was excreted in the urine", and Fukamizu and colleagues write that metabolomic analysis, which "can confirm the bioavailability of NMN", "was not performed during the study period".7,8 App's figureIn the half-life and pharmacokinetics table Route Oral App's modelIn the half-life and pharmacokinetics part
1

Overview

Sources in this part

  1. 3Yoshino et al., 2021

Yoshino and colleagues (Science, 2021) describe NMN as formed from nicotinamide in the primary NAD+ biosynthesis pathway and then converted to NAD+.3 The app lists NMN as an oral supplement in the NAD precursor subcategory and grades its evidence as moderate.

Okabe and colleagues (Frontiers in Nutrition, 2022) write that in the salvage pathway nicotinamide phosphoribosyltransferase makes NMN from nicotinamide, and NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase.1 Christen and colleagues (Nature Metabolism, 2026) propose "a gut-dependent model" in which NMN and nicotinamide riboside raise circulating NAD+ through the Preiss-Handler pathway.4 The model rests partly on ex vivo fermentation with human microbiota, and the authors list as a limitation that they "did not detect increased NA concentrations in the venous whole-blood samples of the study".4 Igarashi and colleagues (npj Aging, 2022) reported that oral NMN "effectively elevated the levels of NMN and NAD+" in whole blood compared with placebo, whereas Okabe and colleagues reported that "NMN levels were not increased after NMN or placebo administration".5,1 In muscle biopsies, Yoshino and colleagues report that "muscle NAD+ and nicotinamide content did not change after 10 weeks of treatment in either group", while NAD+ in blood mononuclear cells rose with NMN.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5 h
Bioavailability
60%
Typical dose
250–1000 mg/day
Route
Oral
Time to peak
~0.25 h

The table sets the app's figures beside what the trial reports give.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~5 h; the app's note gives a plasma half-life of about 5 to 10 minutesNo half-life figure for NMN in people was identified in the trial reports read. The single-dose sampling windows read were 60 minutes in Wakabayashi and colleagues' crossover trial, whose authors say it "precluded the estimation of a full pharmacokinetic profile, including key parameters such as Tmax and total AUC", and 4 h in Christen and colleagues' study.6,4
Bioavailability60%No oral bioavailability figure for NMN was identified in the reports read. Pencina and colleagues report that "Very little unmodified NMN was excreted in the urine", and Fukamizu and colleagues write that metabolomic analysis, which "can confirm the bioavailability of NMN", "was not performed during the study period".7,8
Time to peak~0.25 hAfter 1,000 mg of NMN in 15 healthy adults, whole-blood NMN was not affected, "with no change in the circulatory NAD+ metabolome over 4 h"; the authors note a longer time frame might have captured a longer-term acute effect.4 After 250 mg tablets given orally or sublingually to 13 analysed men, "Blood NMN concentrations showed no change from pre-dose levels with either administration method" over 60 minutes.6
Duration of effect12 hIn Okabe and colleagues' 12-week trial of 250 mg a day, whole-blood NAD+ was raised "at 4-, 8-, 12 weeks, and then returned to basal levels after 16 weeks", four weeks after dosing stopped; the highest level was at 4 weeks.1

Wakabayashi and colleagues (Meiji Holdings, Scientific Reports, 2026) ran a randomized two-period crossover trial in 14 healthy adult men comparing single oral and sublingual NMN, with an 8-day washout and blood samples for 60 minutes.6 The incremental area under the curve for the terminal metabolites 2PY and 4PY was "significantly higher" after sublingual than oral NMN, while blood NMN, nicotinamide, NAD+ and NADP+ did not differ between routes.6 The authors write that "our modest sample size (N = 14) necessitates caution in generalizing the results" and that they "could not completely exclude the contribution of oral ingestion" because saliva was swallowed.6 One participant discontinued after the first intervention because of fever.6 The study was funded from Meiji Holdings internal funds, and its three authors are Meiji Holdings employees.6

Pencina and colleagues (Journal of Gerontology Series A, 2023) gave 32 overweight or obese adults aged 55 to 80 years MIB-626, a microcrystalline polymorph formulation of β-NMN, at 1,000 mg once daily, 1,000 mg twice daily or placebo for 14 days.7 On day 14, blood NMN rose 1.7-fold and 3.7-fold above baseline in mean AUClast in the once-daily and twice-daily groups, and the authors report "substantial dose-related increases in blood NAD levels".7 They report that "MIB-626 was well tolerated and frequency of adverse events was similar across groups".7 Two authors (Lavu and Livingston) are affiliated with Metro International Biotech; only the PubMed record was read, so sponsor, limitations and adverse event counts are not described, and the findings apply to this formulation.7

4

Human studies

The table lists the randomized trials read, other than the single-dose crossover trial described above.

Table 4.1Human studies12 rows
Study and yearDesignPeopleDose and lengthMain result
Yoshino and colleagues, Science 20213Randomized, placebo-controlled, double-blind; supported by NIH grants325 postmenopausal women with prediabetes who were overweight or obese (12 placebo, 13 NMN)3250 mg/day, 10 weeks3Muscle insulin-stimulated glucose disposal was 25±7% greater after than before NMN and not different with placebo; body composition and hepatic and adipose insulin sensitivity did not change; no adverse events reported3
Okabe and colleagues, Frontiers in Nutrition 20221Randomized, double-blind, placebo-controlled; funded by Mitsubishi Corporation Life Sciences130 healthy Japanese adults aged 22 to 64 (15 per group)1250 mg/day (125 mg twice daily), 12 weeks1Whole-blood NAD+ raised at 4, 8 and 12 weeks; symptoms in 8 of 15 NMN and 7 of 15 placebo participants; no serious adverse events1
Igarashi and colleagues, npj Aging 20225Randomized, double-blind, placebo-controlled; funded by Mitsubishi Corporation Life Sciences, which supplied NMN542 men aged 65 or more randomized; 20 in the 12-week analysis after a supplier error5250 mg/day, 6 or 12 weeks5NAD+ and NMN raised in whole blood; "nominally significant" gait speed and left grip changes; no significant effect on body composition; no serious adverse event5
Yi and colleagues, GeroScience 20232Randomized, multicenter, double-blind, placebo-controlled, four arms; funded by Aba Chemicals and Abinopharm280 healthy adults aged 40 to 65, 20 per arm2300, 600 or 900 mg once daily, 60 days2Blood NAD higher than placebo in all NMN arms; 6-minute walk distance longer than placebo; HOMA-IR not different from placebo; nine adverse events, none in the 600 and 900 mg arms2
Fukamizu and colleagues, Scientific Reports 20228Randomized, double-blind, placebo-controlled safety study; funded by Mitsubishi Corporation Life Sciences831 healthy men and women aged 20 to 65 (15 placebo, 16 NMN)81,250 mg once daily, up to 4 weeks8Five adverse events (one in placebo), judged by the investigator to have no direct causal relationship to the test food; no severe adverse events8
Pencina and colleagues, J Gerontol A 20237Double-blind, placebo-controlled; two authors at Metro International Biotech732 overweight or obese adults aged 55 to 807MIB-626 (β-NMN polymorph), 1,000 mg once or twice daily, 14 days7Dose-related increases in blood NAD; adverse event frequency similar across groups7
Christen and colleagues, Nature Metabolism 20264Randomized, open-label, placebo-controlled, four arms; most authors employed by Nestlé465 healthy adults analysed, mean age 34.7 ± 7.4 years; 15 on NMN4NMN 1,000 mg once daily, 14 days (NR 1,000 mg and nicotinamide 500 mg comparators)4Whole-blood NAD+ about 2-fold higher with NMN and NR, not with nicotinamide; three adverse events with a probable relation to the product, one on NMN (headache)4
Kim and colleagues, Nutrients 20229Randomized, double-blind, placebo-controlled, four groups; Mitsubishi Corporation Life Sciences provided the research funds and supplements, and three authors are in its Research and Development Division9108 older Japanese adults9250 mg once daily, 12 weeks9Sit-to-stand improved in all groups including placebo; afternoon NMN largest effect size (d = 0.72); no reported side effects9
Liao and colleagues, J Int Soc Sports Nutr 202110Randomized, double-blind, placebo-controlled, four arms, with exercise training alongside supplementation; national research grant1048 recreationally trained runners (12 per arm)10300, 600 or 1,200 mg/day, 6 weeks10Oxygen uptake, percentage of VO2max and power at the first and second ventilatory thresholds rose more in the 600 and 1,200 mg arms than placebo; no difference in VO2max, O2-pulse, VO2 related to work rate or peak power; no adverse events reported10
Katayoshi and colleagues, Scientific Reports 202311Randomized, double-blind, placebo-controlled; DHC Corporation grant and capsules, and all authors are at DHC Corporation Laboratories1136 healthy middle-aged adults11125 mg twice daily, 12 weeks11Serum nicotinamide higher with NMN; no significant difference in pulse wave velocity; no adverse events11
Morifuji and colleagues, GeroScience 202412Randomized, double-blind, placebo-controlled; funded by Meiji Holdings, whose employees are authors1260 older adults12250 mg/day, 12 weeks12No difference in the primary stepping test; shorter 4-m walk time and better sleep scores at 12 weeks; no related adverse effects12
Akasaka and colleagues, Geriatrics & Gerontology International 202313Placebo-controlled, double-blind; the PubMed record lists a grant from Teijin Ltd., and two authors list Teijin affiliations1314 men aged 65 or more with diabetes and reduced grip strength or walking speed13250 mg/day, 24 weeks13Grip strength and walking speed changes did not differ between groups; no differences in exploratory indicators; no severe adverse events13

A ClinicalTrials.gov query on 16 November 2026 for "nicotinamide mononucleotide" returned 51 studies, including two phase 2 trials listed as recruiting, one in diabetic kidney disease (NCT05759468) and one in cardiac surgery (NCT07013591).

Deeper analysis: Yoshino and colleagues, Science 2021

Yoshino and colleagues at the Center for Human Nutrition, Washington University School of Medicine, reported a 10-week randomized, placebo-controlled, double-blind trial of NMN in postmenopausal women with prediabetes who were overweight or obese.3 Muscle insulin sensitivity, measured as insulin-stimulated glucose disposal per kg of fat-free mass in a clamp, "was 25±7% greater after than before 10 weeks of NMN supplementation" and "was not different after than before placebo treatment".3 The secondary and null results were that hepatic and adipose tissue insulin sensitivity "were not different after than before treatment with either placebo or NMN", and that body composition, fasting glucose, insulin and lipids "did not change in either group after 10 weeks of treatment".3 Muscle function tests "were not affected by 10 weeks of placebo or NMN treatment".3 The study was supported by National Institutes of Health grants, and Oriental Yeast Co. provided the NMN and placebo capsules.3 The competing-interest statement says S.I. "receives a part of patent-licensing fees from MetroBiotech (USA) and Teijin Limited (Japan) through Washington University" and that J.Y. "is an inventor of a patent application related to NMN".3 The authors close by writing that the mechanisms and the potential benefits in other patient populations "remain to be explored"; the trial studied one dose in 25 women.3

Deeper analysis: Okabe and colleagues, Frontiers in Nutrition 2022

Okabe and colleagues at the University of Toyama ran a placebo-controlled, randomized, double-blind, parallel-group trial whose primary outcome was the safety of NMN, with whole-blood NAD+ metabolites as the secondary outcome.1 Symptoms were reported by seven (46.7%) placebo and eight (53.3%) NMN participants, with no serious adverse events in either group.1 One placebo participant discontinued for gastrointestinal symptoms, and none on NMN discontinued.1 Fever, joint pain or fatigue after COVID-19 vaccination was reported by six NMN participants (40.0%) and two placebo participants (13.3%); the authors write that "the difference between the groups was not statistically significant".1 One NMN participant had abdominal pain that began soon after taking NMN and disappeared after 30 minutes, and blood tests differed between groups only for total protein, serum chloride and serum iron at 12 weeks, which were within the normal range in both groups.1 The authors list as limitations that "NAD+ levels in other tissues, such as skeletal muscle, were not examined", that "this study did not demonstrate the consequences of increased NAD+", and that larger samples are needed.1 Mitsubishi Corporation Life Sciences funded the study, and four authors were its employees who "prepared NMN and the placebo".1

Deeper analysis: Yi and colleagues, GeroScience 2023

Yi and colleagues, whose first author is affiliated with Abinopharm, Inc., ran a multicenter trial in healthy adults aged 40 to 65 years, randomized to placebo or once-daily NMN 300, 600 or 900 mg for 60 days, with 20 per arm.2 The primary objective was blood NAD concentration, and all 80 participants completed the trial with a per-protocol analysis.2 NAD was measured as the total of NAD+ and NADH in serum by a colorimetric method; the table prints placebo values of 8.11 ± 5.16, 9.83 ± 8.43 and 11.8 ± 9.4 nM at baseline, day 30 and day 60, and 300 mg values of 11.8 ± 11.7, 29.8 ± 20.1 and 32.6 ± 17.9.2 The authors write that "The 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose".2 HOMA-IR showed no significant difference from placebo, and the authors add that "HOMA-IR increased significantly in both the 600 mg and 900 mg groups" compared with their own baselines.2 Nine adverse events occurred in seven participants: six in five placebo participants and three in two 300 mg participants, none in the 600 and 900 mg arms; the authors state that "All AEs were mild or moderate and none was related to the NMN treatment".2 The authors write that "an even higher number of participants and longer trial duration might have given even more insightful results", and that measuring NAD in whole blood or other tissues "will help gain more comprehensive values".2 The trial was "fully funded by Aba Chemicals Co. (Shanghai, China) and Abinopharm, Inc. (Connecticut, USA)", and one author is an employee of Abinopharm and two of Aba Chemicals.2

Deeper analysis: Igarashi and colleagues, npj Aging 2022

Igarashi and colleagues, at the Department of Diabetes and Metabolic Diseases of the University of Tokyo, gave 250 mg a day of NMN or placebo to men aged 65 or more in a randomized, double-blind, parallel-group trial.5 At the 6-week visit, 11 participants in each group received the other supplement because of a supplier error, so data from 22 people at 12 weeks were excluded and 20 completed (10 per arm in the blood analysis).5 Skeletal muscle mass was unchanged, and the authors describe the gait speed and left grip results as "nominally significant" improvements.5 The paper reports that "NMN exerted no effect on hepatic lipid accumulation and insulin sensitivity".5 The authors name as limitations that excluding 22 participants "disrupted" the balance between groups and "may have compromised some results", that "all analyses were exploratory" with no correction for multiple comparisons, and that only healthy older men were studied.5 Mitsubishi Corporation Life Sciences funded the study and provided the NMN, and three authors are its employees.5

Deeper analysis: Christen and colleagues, Nature Metabolism 2026

Christen and colleagues at Nestlé Research ran a randomized, open-label, placebo-controlled, four-arm study in which healthy adults took NMN 1,000 mg, nicotinamide riboside 1,000 mg, nicotinamide 500 mg or placebo once daily for 14 days; 65 were analysed, 15 of them on NMN.4 The primary endpoint was the change in whole-blood NAD+ after 14 days; NMN raised it about 2-fold, with a difference from placebo of 43.1 µM (95% CI, 32.7–53.4) against 49.4 µM (95% CI, 39.5–59.3) for NR, while nicotinamide did not raise it.4 Three adverse events had a probable relation to the product: abdominal pain on placebo, hypotension on NR and headache on NMN.4 The authors write that the study "was performed with a healthy population, and NAD+ concentrations were raised above normal values".4 Ten authors are employees of Nestlé Research, one of Nestlé Health Science and one of Cryptobiotix SA; the text read carries no separate funding statement.4

Deeper analysis: Fukamizu and colleagues, Scientific Reports 2022

Fukamizu and colleagues, five of six of whom are employees of Mitsubishi Corporation Life Sciences, reported a randomized, double-blind, placebo-controlled safety study of 1,250 mg of β-NMN once daily for up to 4 weeks in 31 healthy adults aged 20 to 65.8 The study was conducted at Pharma Foods Co., Ltd. and funded by Mitsubishi Corporation Life Sciences, which supplied the NMN but, according to the disclosure, "was not involved in the conduct and data analysis of the human clinical study".8 Five adverse events were recorded (loose stool on placebo; common cold, high blood pressure, loose stool and acne vulgaris on NMN), and the principal investigator judged that none had a direct causal relationship to the test food.8 The authors list limitations: metabolomics "was not performed during the study period" and "our study was relatively small".8

5

Doses reported in studies and on labels

The table lists the doses given in the studies above and on the one single-ingredient DailyMed label found.

Table 5.1Doses reported in studies and on labels14 rows
SourceDose and routeComparatorLengthParticipants
Yoshino 20213250 mg/day by mouthPlacebo10 weeks25 (12 placebo, 13 NMN)
Okabe 20221125 mg twice daily by mouthPlacebo12 weeks30
Igarashi 20225250 mg once daily by mouthPlacebo12 weeks42 randomized; 20 in the 12-week analysis
Kim 20229250 mg once daily, morning or afternoonPlacebo, morning or afternoon12 weeks108 in four groups
Katayoshi 202311125 mg twice daily (250 mg/day)Placebo12 weeks36
Morifuji 202412250 mg/dayPlacebo12 weeks60
Akasaka 202313250 mg/day by mouthPlacebo24 weeks14
Yi 20232300, 600 or 900 mg once daily by mouthPlacebo60 days80 (20 per arm)
Liao 202110300, 600 or 1,200 mg/dayPlacebo6 weeks48 (12 per arm)
Christen 20264NMN 1,000 mg once dailyPlacebo (open-label)14 days65 analysed (15 on NMN)
Pencina 20237MIB-626 (β-NMN polymorph), 1,000 mg once or twice dailyPlacebo14 days32
Fukamizu 202281,250 mg once daily by mouthPlaceboUp to 4 weeks31 (15 placebo, 16 NMN)
Wakabayashi 20266Single administration of tablets containing 250 mg of β-NMN, oral and sublingualCrossover (each man on both routes)60 minutes of sampling; 8-day washout14 enrolled, 13 analysed
ELITEHEALTH capsule label (DailyMed, 2023)14500 mg of β-nicotinamide mononucleotide per capsule; the label lists one capsule per dayNot applicableNot statedNot applicable

Per-trial counts are in the table and analyses above; Okabe and colleagues reported symptoms in 8 of 15 NMN and 7 of 15 placebo participants, and Fukamizu and colleagues recorded five adverse events including loose stool, common cold, high blood pressure and acne vulgaris.1,8 Kim, Liao, Katayoshi and Morifuji and colleagues report no side effects or adverse events related to NMN, and Akasaka and colleagues report "no severe adverse events" in 14 older men with diabetes.9,10,11,12,13

7

Bloodwork and markers

Sources in this part

  1. 2Yi et al., 2023

The app lists whole-blood NAD+ as the marker to monitor. Yi and colleagues note that "the analytical methods of blood samples affect the results of final blood NAD concentrations".2 In Yi and colleagues' day-60 chemistry table, LDL cholesterol was 119 ± 34 mg/dL on placebo and 146.00 ± 36.90 in the 900 mg arm (p printed as 0.02), against baseline values of 114 ± 30 and 132.80 ± 39.70.2 The authors report that the three NMN groups did not differ from placebo in the clinical laboratory parameters except MCHC and LDL at 900 mg and uric acid nitrogen at 600 mg, and that no abnormality was observed in the clinical laboratory parameters of all participants.2

8

Regulatory and anti-doping status

A letter dated 29 September 2025 from the FDA Human Foods Program responds to a Council for Responsible Nutrition citizen petition about β-nicotinamide mononucleotide (docket FDA-2023-P-1867) and states that the petition "is granted in part and denied in part".15 One heading in the letter reads "FDA Will Not Issue Guidance Relating to Drug Exclusion Exceptions at This Time".15 The letter incorporates by reference a companion response to a Natural Products Association and Alliance for Natural Health petition (docket FDA-2023-P-0872), which was not read, so the letter as read does not itself state whether NMN may be sold as a dietary supplement.15 The app's note states that FDA reclassified NMN as a drug investigation in 2022; the letter read does not mention 2022.15 The 2026 WADA Prohibited List text read does not name NMN or nicotinamide mononucleotide; its only match for "nicotin" is nicotine.16

9

Storage and handling

Sources in this part

  1. 14MOHAMMEDJALI Co., 2023

The one single-ingredient DailyMed label found says "Store in a cool, dry place away from excessive heat" and carries a pregnancy and breastfeeding warning.14

No half-life, oral bioavailability or time to peak for NMN in people was identified in the reports read; the app's figures for these have no matching source figure. Whether a higher blood NAD+ leads to benefit is not settled by these trials: Okabe and colleagues write that their study "did not demonstrate the consequences of increased NAD+", and Akasaka and colleagues report no difference in grip strength or walking speed.1,13 Fukamizu and colleagues write that "a long-term intake safety study or cohort study is needed".8 A PubMed query on 16 November 2026 for sublingual nicotinamide mononucleotide returned one record, a crossover trial of 14 men (13 analysed) sampled for 60 minutes, whose authors call it "preliminary human evidence".6

What is the half-life of NMN?

The app lists a half-life of about 5 hours and its note gives a plasma half-life of about 5 to 10 minutes, and no half-life figure for NMN in people was identified in the trial reports read.

How long does NMN take to reach its peak level?

The app lists a time to peak of about 0.25 hours (15 minutes), while Christen and colleagues reported no change in the circulatory NAD+ metabolome over 4 hours after NMN.4 Wakabayashi and colleagues sampled for 60 minutes and state that this "precluded the estimation" of Tmax.6

What is the bioavailability of NMN?

The app lists an oral bioavailability of 60%, and none of the reports read gives an oral bioavailability figure.

Does NMN raise NAD+ in people?

Whole-blood NAD+ was higher with oral NMN than placebo in Okabe and colleagues' 12-week trial at 250 mg a day and in Christen and colleagues' 14-day trial at 1,000 mg a day, while Katayoshi and colleagues reported serum NAD below 5 ng/mL in both groups and Christen and colleagues reported no change in the circulatory NAD+ metabolome over 4 h in their acute arm.1,4,11

Is NMN banned by WADA?

The 2026 WADA Prohibited List text read does not name NMN or nicotinamide mononucleotide.16

What did the FDA say about NMN in September 2025?

An FDA letter dated 29 September 2025 granted in part and denied in part a Council for Responsible Nutrition petition about NMN.15

What side effects were reported in NMN trials?

In the trials read, Yi and Fukamizu and colleagues' investigators judged none of the adverse events related to NMN, while Okabe and colleagues recorded one NMN participant with abdominal pain counted as due to the intervention and Christen and colleagues recorded one headache on NMN among three adverse events with a probable relation to the product.2,8,1,4

Has sublingual NMN been compared with oral NMN in people?

A PubMed query on 16 November 2026 returned one crossover trial of 14 healthy men (13 analysed), which found higher early terminal metabolites 2PY and 4PY after sublingual than oral NMN, with no difference in blood NMN, nicotinamide or NAD+ over 60 minutes.6

13

References

  1. Okabe K, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr 2022. PMID 35479740
  2. Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience 2023. PMID 36482258
  3. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021. PMID 33888596
  4. Christen S, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab 2026. PMID 41540253
  5. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging 2022. PMID 35927255
  6. Wakabayashi J, et al. Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men. Sci Rep 2026. PMID 42304075
  7. Pencina KM, et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci 2023. PMID 35182418
  8. Fukamizu Y, et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep 2022. PMID 36002548
  9. Kim M, et al. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients 2022. PMID 35215405
  10. Liao B, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr 2021. PMID 34238308
  11. Katayoshi T, et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep 2023. PMID 36797393
  12. Morifuji M, et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience 2024. PMID 38789831
  13. Akasaka H, et al. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study. Geriatr Gerontol Int 2023. PMID 36443648
  14. MOHAMMEDJALI Co., Ltd. ELITEHEALTH (nicotinamide mononucleotide) capsule. DailyMed label, version 1, 2023. DailyMed label
  15. U.S. Food and Drug Administration, Human Foods Program. Response to citizen petition, docket FDA-2023-P-1867, 29 September 2025. FDA letter
  16. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list